Ultra Health Care





Semi-annual Shareholder Report - November 30, 2024

This Semi-annual shareholder report contains important information about Ultra Health Care (the "Fund") for the period of June 1, 2024 to November 30, 2024. You can request additional information about the Fund by contacting us at 866-776-5125. You can also find additional information about the Fund at: https://www.proshares.com/geared_shareholder_reports.

What were the Fund's costs for the period?

(based on a hypothetical \$10,000 investment)

Ticker	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment*
RXL	\$48	0.95%
* Annualized		

Key Fund Statistics				
Net Assets	\$84,883,711			
Number of Portfolio Holdings	71			
Portfolio Turnover Rate	1%			

Market Exposure			
Investment Type	% of Net Assets		
Equity Securities	69%		
Swap Agreements	131%		
Total	200%		

[&]quot;Market Exposure" includes the value of total investments (including the contract value of any derivatives) and excludes any short-term investments and cash equivalents.

Largest Holdings				
Holdings	% of Net Assets			
Eli Lilly & Co.	8.1%			
UnitedHealth Group, Inc.	7.2%			
Johnson & Johnson	4.8%			
AbbVie, Inc.	4.2%			
Merck & Co., Inc.	3.3%			
Abbott Laboratories	2.7%			
Thermo Fisher Scientific, Inc.	2.6%			
Intuitive Surgical, Inc.	2.5%			
Danaher Corp.	2.0%			
Amgen, Inc.	2.0%			

Sector Weights	
Sector	% of Exposure
Pharmaceuticals	30.3%
Health Care Providers & Services	22.2%
Health Care Equipment & Supplies	21.9%
Biotechnology	15.6%
Life Sciences Tools & Services	10.0%

Ultra Health Care - RXL

Semi-annual Shareholder Report - November 30, 2024

If you wish to view additional information about the Fund; including but not limited to financial statements or holdings, please visit www.proshares.com or by calling ProShares Trust at 866-776-5125.

